Table 2: Summary of ECG Measures, Mean (Change from Baseline)

ECG Measure Placebo (N=28) Albuterol HFA 90µg TID (N=29) Albuterol HFA 180µg TID (N=29)
Heart Rate (bpm)
 Baselinea 127.2 132.4 128.6
 Week 4 Pre-dosec 126.4 (-2.0) 126.3 (-5.4) 128.1 (-1.6)
 Week 4 Post-dosec 123.9 (-4.5) 129.0 (-2.9) 132.7 (3.0)
QT Interval (msec)
 Baselinea 279.1 275.4 273.4
 Week 4 Pre-Dosec 279.8 (2.3) 279.1 (0.7) 274.9 (1.0)
 Week 4 Post-dosec 279.0 (1.5) 279.0 (2.3) 276.1 (2.3)
QTc Intervalb (msec)
 Baselinea 357.1 357.7 350.7
 Week 4 Pre-Dosec 357.8 (1.7) 356.5 (-4.4) 352.2 (0.0)
 Week 4 Post-dosec 354.0 (-2.0) 358.2 (-0.7) 358.5 (6.3)
PR Interval (msec)
 Baselinea 111.6 116.5 111.3
 Week 4 Pre-Dose 115.4 118.5 110.7
 Week 4 Post-dose 114.4 118.2 114.1
QRS Duration (msec)
 Baselinea 67.5 66.2 66.2
 Week 4 Pre-Dose 68.3 67.4 66.3
 Week 4 Post-dose 68.4 66.8 67.2

HFA, hydrofluoroalkane; TID, three times daily.
a Baseline, value obtained at Screening Visit.
b Corrected for heart rate using Fredericia's formula.
c Value is Raw Value and (Change from Baseline).